Advertisement

Effects of Drug Interactions

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Several cardiac drugs manifest some form of interaction with each other or with non-cardiac drugs. It is of paramount importance for the physician to be aware of these interactions, which may be potentially harmful to patients or may negate salutary effects. In addition, the prescribing physician must be conscious of these interactions so as to avoid errors that may provoke medicolegal action.

Keywords

Complete Heart Block Right Bundle Branch Block Coronary Artery Spasm Digoxin Level Right Bundle Branch Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McLay JS, McMurray JJ, Bridges AB, et al. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 1993;126: 879.PubMedCrossRefGoogle Scholar
  2. 2.
    Ochs HR, Carstens G, Greenblatt DJ. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980 303:373.PubMedCrossRefGoogle Scholar
  3. 3.
    Trohman RG, Estes DM, Castellanos A, et al. Increased quinidine plasma concentration during administration of verapamil: A new quinidine-verapamil interaction. Am J Cardiol 1986;57:706.PubMedCrossRefGoogle Scholar
  4. 4.
    Becker RC, Caputo R, Ball S, et al. Hemorrhagic potential of combined diltiazem and recombinant tissuetype plasminogen activator administration. Am Heart J 126: 11, 1993.PubMedCrossRefGoogle Scholar
  5. 5.
    Gore JM, Sloan M, Price TR, et al. and the TIMI Investigators. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarcttion and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study. Circulation 1991;83:448.PubMedGoogle Scholar
  6. 6.
    Blum CB. Comparison of properties of four inhibitors of 3-hydro xy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D.PubMedCrossRefGoogle Scholar
  7. 7.
    Browne KF, Prystowsky EN, Neger JJ, et al. Prolongation of the QT interval induced by probucol: Demonstration of a method for determining QT interval change induced by a drug. Am Heart J 1984;107:680.PubMedCrossRefGoogle Scholar
  8. 8.
    Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990;51:385.PubMedGoogle Scholar
  9. 9.
    Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991;52:174.PubMedGoogle Scholar
  10. 10.
    Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry 1991;52:139.PubMedGoogle Scholar
  11. 11.
    Zipes DP. Unwitting exposure to risk. Cardiol Rev 1993;1:1.CrossRefGoogle Scholar
  12. 12.
    Stramha-Badiale M, Guffanti S, Porta N, et al. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am Heart J 1993;126:740.CrossRefGoogle Scholar
  13. 13.
    Nosten F, terKuile FO, Luxemburger C. Cardiac effects of anti-malarial treatment with halofantrine. Lancet 1993;341:1054.PubMedCrossRefGoogle Scholar
  14. 14.
    Martyn R, Somberg JC, Kerin NZ. Proarrhythmia of nonanti-arrhythmia drugs. Am Heart J 1993; 126: 201.PubMedCrossRefGoogle Scholar
  15. 15.
    Simons FER, Simons KJ, Wood AJJ. The pharmacology and use of Hj-receptor-antagonist drugs. N Engl J Med 1994;330:1663.PubMedCrossRefGoogle Scholar
  16. 16.
    Glassman AH, Roose SP, Bigger JT. The safety of tricyclic antidepressants in cardiac patients. JAMA 1993;269:2673.PubMedCrossRefGoogle Scholar
  17. 17.
    Belmonte MA, Cequiere A, Roig-Escofet D. Severe ventricular arrhythmia after methylprednisone pulse therapy in rheumatoid arthritis. J Rheumatol 1986;13:477.PubMedGoogle Scholar
  18. 18.
    Ottervanger JP, Paalman HJA, Boxma GL, et al. Transmural myocardial infarction with sumatriptan. Lancet 1993;341:861.PubMedCrossRefGoogle Scholar
  19. 19.
    Esselink RAJ, Gerding MN, Brouwers PJAM, et al. Total heart block after intravenous metoclopramide. Lancet 1994;343:182.CrossRefGoogle Scholar
  20. 20.
    Brown DL, Sather S, Cheitlin MD. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 1993;125:1439.PubMedCrossRefGoogle Scholar
  21. 21.
    Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker WP, Dainer P, Lester WM, et al. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986;57:497.PubMedCrossRefGoogle Scholar
  23. 23.
    Cheng TO. Interaction of herbal drugs with digoxin. J Am Coll Cardiol 2002;40:838.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Jhund P, McMurray JJV. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor?: Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006;113:2566–2568.PubMedCrossRefGoogle Scholar
  2. O’Gara PT. Common drug interactions in cardiology. ACC Curr J Rev Jul/Aug:l, 2002.Google Scholar
  3. Valli G, Giardina EV. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 2002;39:1083.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations